ULURU Inc. Presents Data on Negative Pressure Related to Altrazeal(TM) at the Diabetic Limb Salvage Conference in Washington, D.
25 September 2009 - 1:18AM
PR Newswire (US)
ADDISON, Texas, Sept. 24 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE
Alternext: ULU) announced today the presentation of important
clinical data and research at the 2009 Diabetic Limb Salvage (DLS)
Conference in Washington, D.C. One poster presentation demonstrates
the physics and modeling of Altrazeal and the mechanism for exudate
management and the generation of low pressure when in place on a
wound. John St. John, PhD, Vice President of Research and
Development for ULURU Inc. commented, "This data explains how
Altrazeal was designed using patented Nanoflex(TM) Technology to
provide maximum moisture vapor transpiration and how capillary
forces provide decreased pressure without an external vacuum pump."
A second poster presentation will provide data and analysis of the
recently concluded randomized clinical study of Altrazeal in split
thickness skin graft donor sites. The poster will focus on the
decrease in pain and improved patient comfort associated with what
is traditionally a painful wound. Renaat Van den Hooff, President
and CEO of ULURU Inc., commented, "We are again very pleased to be
able and present new and exciting data related to Altrazeal at this
important conference. We continue to dedicate ourselves to building
a base of clinical evidence and I look forward to interactions with
some of the leaders in healing diabetic wounds at this important
research meeting." The Diabetic Limb Salvage Conference takes place
in Washington, D.C. and at Georgetown University Hospital September
24-26, 2009. More information about the conference can be found at
http://www.dlsconference.com/index.html About ULURU Inc.: ULURU
Inc. is a specialty pharmaceutical company focused on the
development of a portfolio of wound management and oral care
products to provide patients and consumers improved clinical
outcomes through controlled delivery utilizing its innovative
Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal
delivery system. For further information about ULURU Inc., please
visit our website at http://www.uluruinc.com/. For further
information about Altrazeal(TM), please visit
http://www.altrazeal.com/. This press release contains certain
statements that are forward-looking within the meaning of Section
27a of the Securities Act of 1933, as amended, including but not
limited to statements made relating to the benefits, effectiveness,
success in wound healing, clinical outcomes, and suitability of
Altrazeal(TM), and the success of our clinical efforts. These
statements are subject to numerous risks and uncertainties,
including but not limited to the risk factors detailed in the
Company's Annual Report on Form 10-K for the year ended December
31, 2008, and other reports filed by us with the Securities and
Exchange Commission. Contact: Company Renaat Van den Hooff
President & CEO Terry K. Wallberg Vice President & CFO
(214) 905-5145 DATASOURCE: ULURU Inc. CONTACT: Renaat Van den
Hooff, President & CEO, or Terry K. Wallberg, Vice President
& CFO, both of ULURU Inc., +1-214-905-5145 Web Site:
http://www.uluruinc.com/
Copyright